Soft tissue limb sarcomas

Of the different options for limb‐sparing treatment for patients with soft tissue limb sarcomas (STLS), hyperthermic antiblastic perfusion (HAP) combined with surgery might be the most effective in terms of tumor resectability, local control, and aesthetic and functional results. The aim of this study was to identify the most safe, active, and effective perfusional regimen in order to improve multidisciplinary treatment for patients with advanced STLS.

[1]  P. Hohenberger,et al.  Clinical Management and Current Research in Isolated Limb Perfusion for Sarcoma and Melanoma , 1998, Oncology.

[2]  M. Gebhardt,et al.  Prognostic factors for local control of sarcomas of the soft tissues managed by radiation and surgery. , 1997, Seminars in oncology.

[3]  P. Schlag,et al.  Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. , 1996, Annals of surgery.

[4]  M. Lise,et al.  TNF-alpha and doxorubicin in hyperthermic perfusion for limb sarcomas. , 1996, Oncology reports.

[5]  M. Lise,et al.  Limb‐sparing treatment for soft tissue sarcomas: Influence of prognostic factors , 1996, Journal of surgical oncology.

[6]  M. Lise,et al.  Multimodality treatment of extra-visceral soft tissue sarcomas M0: state of the art and trends. , 1995, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[7]  A. Eggermont,et al.  Clinical experience with high-dose tumor necrosis factor alpha in regional therapy of advanced melanoma. , 1994, Circulatory shock.

[8]  V. Ninfo,et al.  Phase II study on neoadjuvant hyperthermic‐antiblastic perfusion with doxorubicin in patients with intermediate or high grade limb sarcomas , 1994, Cancer.

[9]  L. Ellis,et al.  Influence of surgical margins on outcome in patients with preoperatively irradiated extremity soft tissue sarcomas , 1994, Cancer.

[10]  A. Eggermont,et al.  Systemic leakage during isolated limb perfusion for melanoma , 1993, The British journal of surgery.

[11]  J. Thomas,et al.  Low‐dose tumour necrosis factor α and melphalan in hyperthermic isolated limb perfusion , 1993 .

[12]  E. Casper,et al.  Refinement of clinicopathologic staging for localized soft tissue sarcoma of the extremity: a study of 423 adults. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  M. Zelefsky,et al.  Limb salvage in soft tissue sarcomas involving neurovascular structures using combined surgical resection and brachytherapy. , 1990, International journal of radiation oncology, biology, physics.

[14]  P. Schlag,et al.  Hyperthermic limb perfusion for malignant melanoma and soft tissue sarcoma. , 1990, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[15]  R. Benjamin,et al.  Preoperative Chemotherapy for Soft‐tissue Sarcomas of the Extremities , 1990, Annals of surgery.

[16]  C. Fisher,et al.  The influence of local recurrence of extremity soft tissue sarcoma on metastasis and survival , 1990, Cancer.

[17]  B. Kroon,et al.  Results of regional isolation perfusion with cytostatics in patients with soft tissue tumors of the extremities , 1989, Cancer.

[18]  J. Petiot,et al.  Prognostic factors in soft tissue sarcomas. A multivariate analysis of 109 cases , 1989, Cancer.

[19]  Y. Niitsu,et al.  Synergistic effects of recombinant human tumor necrosis factor and hyperthermia on in vitro cytotoxicity and artificial metastasis. , 1988, Cancer research.

[20]  W. Molenaar,et al.  Results of isolated regional perfusion in the treatment of malignant soft tissue tumors of the extremities , 1987, Cancer.

[21]  D. S. Coffey,et al.  Synergistic enhancement by tumor necrosis factor of in vitro cytotoxicity from chemotherapeutic drugs targeted at DNA topoisomerase II. , 1987, Cancer research.

[22]  K. Stevens,et al.  Improved survival for soft tissue sarcoma of the extremities by regional hyperthermic perfusion, local excision and radiation therapy. , 1986, Surgery, gynecology & obstetrics.

[23]  E. Krementz,et al.  Regional perfusion: Current sophistication, what next? , 1986 .

[24]  E. McFadden,et al.  Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.

[25]  E. V. van Slooten,et al.  Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. , 1982, European journal of cancer & clinical oncology.

[26]  B. Stener,et al.  A multivariate analysis of the prognosis after surgical treatment of malignant soft‐tissue tumors , 1982, Cancer.

[27]  D. Morton,et al.  Is Amputation Necessary for Sarcomas? A Seven‐Year Experience with Limb Salvage , 1980, Annals of surgery.

[28]  H. Wanebo,et al.  Soft tissue sarcoma. , 1997, Medicine and health, Rhode Island.

[29]  J. Godbold,et al.  Prognostic factors for local recurrence and survival in patients with localized extremity soft-tissue sarcoma. , 1988, Seminars in surgical oncology.

[30]  B. Giovanella,et al.  15 years' experience with hyperthermic perfusion for treatment of soft tissue sarcoma and malignant melanoma of the extremities. , 1984, Frontiers of radiation therapy and oncology.